Our story: Neurophoral

Jan 13

Not long ago, people in brain health kept telling us the same thing:

“We don’t need more noise… we need smarter scaffolds.”

That idea led our team at Biotech International Institute (BII) to rethink how we approach cannabinoid-inspired neurobiology, instead of just making minor changes to THC.

The key shift was to stop modifying THC and instead redesign the core structure.

For decades, most cannabinoid chemistry has relied on the dibenzo[b,d]pyran scaffold, which is the main structure found in THC-like compounds. BII’s Neurophorol

The program was started to explore a new path: using a different framework based on a dibenzo[a,e]pyran (xanthene) scaffold. This change is meant to alter the molecule’s fundamental structure, 3D shape, and its interactions with biological systems. Forming a new pathway to explore in medicine, chemistry, and biochemistry.

What Neurophorol™ is (and what it’s not)

Neurophorol™ is a research-focused, experimental scaffold meant for careful study, not for hype. Our goals are to explore a CB₂-biased profile instead of CB₁, lower the psychoactive risk linked to CB₁ compared to THC-like scaffolds, and test broader ideas about neuroinflammation and oxidative stress in preclinical models.

The science questions we’re actively building around

The Neurophorol™ research plan focuses on three main areas, which we are looking towards:

CB₂-linked neuroinflammation modulation and how to bypass it (microglia/cytokine-related pathways)
Oxidative stress & redox balance (xanthene-linked redox chemistry hypotheses)
Synaptic and cognitive network support (studied in model systems, not in humans)

It is important to note that Neurophorol™ is not an approved drug, and we do not claim it can prevent, treat, reduce, or cure any disease.

Why we’re sharing this now

This is what responsible innovation means to us: start with a new scaffold, create testable ideas, be clear about limitations, and validate results carefully.

If you work in neurobiology, medicinal chemistry, translational R&D, or cannabinoid receptor science—here’s the real question:

When you see a “new scaffold,” what matters most first?